|  |  |  |  |
| --- | --- | --- | --- |
| **Study Groups** | **Rate of bleeding in study group (%)** | **Rate of overall bleeding in  control group (n = 509) (%)** | ***p*-value** |
| **Aspirin only** **(n = 62)** | 0.00% | 1.37% | - |
| **Aspirin + SQ Heparin (n = 317)** | 1.26% | 1.37% | 0.45 |
| **Clopidogrel only** **(n = 70)** | 4.28% | 1.37% | 0.03\* |
| **Clopidogrel + SQ Heparin** **(n = 32)** | 3.12% | 1.37% | 0.21 |
| **Aspirin + Clopidogrel** **(n = 25)** | 4.00% | 1.37% | 0.14 |
| **Aspirin + Clopidogrel + SQ Heparin****(n = 90)** | 0.00% | 1.37% | - |
| **Warfarin only** **(n = 97)** | 0.00% | 1.37% | - |
| **Warfarin + DOAC** **(n = 24)** | 0.00% | 1.37% | - |
| **DOAC Only** **(n = 24)** | 0.00% | 1.37% | - |

**Supplemental Table 1: Case control analysis of rate of overall bleeding in study groups versus control group (SQ heparin)**

**(SQ Heparin: Subcutaneous Heparin, DOAC: Direct Oral Anticoagulants)**